1. Gerhard Bühringer, Monika Sassen Institut für Klinische Psychologie und Psychotherapie Institut für Therapieforschung, München EMCDDA work and scientific publishing in peer-reviewed journals Scientific Committee meeting November 17/18, 2008

2. 2 Content 1.Key questions 2.EMCDDA products 3.Structure of products 4.Suggested procedure

3. 3 1. Key questions How can the EMCDDA improve its scientific profile? How can the number of publications on EMCDDA work in peer- reviewed journals be increased? How can the Scientific Committee contribute to this?

4. 4 2. EMCDD Products ProductContentTarget groupExample Annual Report EMCDDA's yearly overview of the drug phenomenon (Published every autumn) Policymakers & their advisors (primary target) specialists & practitioners in the drugs field Drug related infectious diseases General report of activities annual publication providing a detailed progress report of the EMCDDA's activities over a 12-month period European institutions EMCDDA statutory bodies drug-related bodies in the EU Member States international organisations Drugnet Europe the EMCDDA's newsletter (four issues published per year) EMCDDA partners: focal points & international institutions practitioners in drugs field scientists & researchers European citizens Drugs in focus a series of policy briefings from the EMCDDA (published three times per year) Policymakers & their advisorsSubstance use among older adults: a neglected problem Cocaine use in Europe: implications for service delivery; Drugs and crime - a complex relationship

5. 5 2. EMCDD Products ProductContentTarget groupExample Insights volumes conveying the findings of study and research carried out by the agency on topical issues in the drugs field Policymakers & their advisors specialists & practitioners in the drugs field. Prevention of substance abuse (2008) An overview of cannabis potency in Europe (2004) Prosecution of drug users in Europe - varying pathways to similar objectives (2002) Literature reviews bring the reader up-to-date with current knowledge on a particular topic highlighting areas that still need research and development Specialists & practitioners in the drugs field (including scientists & academics) policymakers. Treatment of problem cocaine use: a review of the literature (2007) Monographs specialised publications containing scientific papers prepared in the context of EMCDDA research studies, conferences and seminars Specialists & practitioners in the drugs field, (including scientists & academics - primary target) policymakers & their advisors A cannabis reader: global issues and local experiences (2008) Hepatitis C and injecting drug use: impact, costs and policy options (2004) Modelling drug use: methods to quantify and understand hidden processes (2001) Manuals practical handbooks aimed at professionals and grassroot practitioners working in the drugs field Practitioners in the drugs field Guidelines for the evaluation of treatment in the field of problem drug use (2007) Guidelines for the evaluation of outreach work: a manual for practitioners (2001) Guidelines for the evaluation of drug prevention: a manual for programme- planners and evaluators (1998)

6. 6 2. EMCDD Products ProductContentTarget groupExample Risk assessments results of the agency's work under the terms of the Action on new drugs (formal risk assessments of a number of substances) Action on new drugs European institutions international organisations drug-related bodies in the EU Member States; EMCDDA statutory bodies; journalists. Selected issues in-depth reviews of topical interest based on information provided to the EMCDDA by the Reitox national focal points as part of the national reporting process Policymakers & their advisors specialists & practitioners in the drugs field Vulnerable groups of young people (2008) National drug-related research in Europe (2008) Towards a better understanding of drug-related public expenditure in Europe (2008) Thematic papers scientific papers on selected, theme-based aspects of the drugs phenomenon specialists & practitioners in the drugs field (including scientists & academics) policy-makers GHB and its precursor GBL: an emerging trend case study (2008) Hallucinogenic mushrooms (2006) Youth media (2005) Technical datasheets present and discuss information on ongoing EMCDDA research topics Specialists & practitioners in the drugs field (including scientists & academics) Monitoring the supply of cocaine to Europe (2008) Monitoring the supply of heroin to Europe (2008) Sexual assaults facilitated by drugs or alcohol (2008)

7. 7 3. Structure of products quantitative analysesqualitative analyses original papers reviews position papers guidelines commissioned products internal products

8. 8 4. Suggested procedures I 4.1 Commissioned products preparation of tenders: –consider possible (sub-) topics for publications in the tender specification: –specify expected publications –Consider time requirements during selection process: –consider scientific (publishing) qualifications during product development: –monitor manuscript development and submission (e.g., selection of journal) –clarify function of EMCDDA “project manager” as possible co- author (ISAJE/PAS2: authorship checklist) –provide standardized “acknowledgement statement”

9. 9

10. 10

11. 11 4. Suggested procedures II Cave! –Pre-publishing of manuscript contents in EMCDDA publications might be a risk for scientific publishing. Function of the Scientific Committee –advice for selection of “publishable items” –evaluation of manuscript quality –advice for selection of journals –possible authorship

12. 12 4. Suggested procedures III 4.2 Internal products preparation of task/project: –consider possible subtopics for publication during planning process: –consider publication task and time requirements staff selection: –consider scientific and publication competences and/or –look for external co-authors during product development: –clarify authorship –allocate tasks – select the journal (manuscript requirements)

13. 13 4. Suggested procedures IV Cave! –Pre-publishing of manuscript contents in EMCDDA publications might be a risk for scientific publishing. Function of the Scientific Committee –advice for selection of “publishable items” –evaluation of manuscript quality –advice for selection of journals –possible authorship